Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Maze Therapeutics (NASDAQ:MAZE) from a sell rating to a hold rating in a research report sent to investors on Sunday.

MAZE has been the subject of several other research reports. Guggenheim reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Friday, December 19th. Raymond James Financial began coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday. Wedbush upped their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, HC Wainwright increased their price target on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $44.50.

Maze Therapeutics Price Performance

MAZE opened at $44.27 on Friday. The stock has a market cap of $2.13 billion and a P/E ratio of -2.12. The stock’s 50 day simple moving average is $39.90 and its 200 day simple moving average is $28.15. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $47.36.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Insider Activity

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of the business’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Amy Bachrodt sold 10,000 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at approximately $526,119.70. This represents a 43.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 167,500 shares of company stock valued at $6,774,667 over the last 90 days.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new stake in Maze Therapeutics in the 1st quarter worth about $145,000. Ensign Peak Advisors Inc acquired a new position in shares of Maze Therapeutics during the 2nd quarter valued at about $227,000. Frazier Life Sciences Management L.P. lifted its holdings in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after acquiring an additional 438,274 shares during the period. Virtus Investment Advisers LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter worth about $85,000. Finally, CW Advisors LLC acquired a new stake in shares of Maze Therapeutics in the second quarter worth approximately $371,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.